Top 10 article countdown: Oncology Central 2023
As we approach 2024, we take a look back at the top articles from Oncology Central of 2023. We hope you enjoy our selection and look forward to what next year has in store!
AACR 2023: AEGEAN trial demonstrates improved OS for durvalumab NSCLC treatment arm
Nabbing 10th place is a news story from the AACR Annual Meeting 2023 (April 14−19 2023, FL, USA). The Phase III AEGEAN trial saw patients with treatment-naïve NSCLC treated with neoadjuvant Imfinzi® (durvalumab), plus chemotherapy with further adjuvant durvalumab monotherapy, showing an increase in event-free survival with complete pathological complete response.
IKEMA study: improving outcomes for multiple myeloma patients
Our most viewed video of 2023 was centred around the IKEMA study, which is a randomized Phase III trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd for relapsed multiple myeloma patients. Find out what the next steps are for this study here.
ASCO 2023: a collection of breaking news stories
Trastuzumab deruxtecan claimed the spotlight in being our most read individual news piece around ASCO, however, our collection of headlines from the conference also gained a lot of traction. Key stories noted in this roundup include adjuvant Kisqali® (ribociclib) yielding promising results for early-stage breast cancer and Keytruda® (pembrolizumab) plus chemotherapy improving overall survival for some cervical cancer patients.
Does lowering alcohol intake reduce the risk of cancer?
Taking the 7th place, Rachel Clark (WCRF, UK) delves into the latest evidence-based research surrounding the multiple ways in which alcohol is thought to increase cancer risk and what people can do to reduce their risk. Gain insights into evidence-based research and learn how lifestyle choices can impact cancer prevention.
US FDA approves ORSERDU™ (elacestrant) for ER+, HER2- advanced or metastatic breast cancer
In the 6th place, witness a groundbreaking approval as the US FDA gives the green light to Orserdutm (elacestrant) for the treatment of postmenopausal women or adult men with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer with disease progression, following at least one line of endocrine therapy. The drug is the first ever therapy specifically for patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer.
ASCO23: trastuzumab deruxtecan proves to be effective on multiple HER-2 expressing tumors
From our ASCO coverage, the standout was the DESTINY-PanTumor02 study. Lead author Funda Meric-Bernstam (TX, USA) explained: “These results advance our clinical understanding of HER2 expression, reaffirm HER2 as an actionable biomarker across a broad range of tumor types, and show that trastuzumab deruxtecan could potentially provide a new treatment option.”
Tackling disparities in cancer care across Europe: how can we improve access in Europe?
Across Europe there are significant disparities in access to cancer care. Access to new medicines varies from 4 months to almost 2 years post-market authorization across countries and regions. Securing 4th place, this opinion piece explores potential innovative solutions to address these disparities.
Top 3 drug approvals March 2023: Zynyz®, Calquence®, Keytruda®
At the start of 2023, the US FDA began reigning in their accelerated approval program, as it received criticism over approvals based on single-arm clinical trials, meaning a drop in drug recommendations. Despite this, in March we saw a few new treatment modalities being given the green light, including those for Merkel cell carcinoma, cervical cancer and mantle cell lymphoma, pipping this article into third place on our countdown.
TVEC: a breakthrough for triple-negative breast cancer patients?
Coming in silver, our top news article of 2023 highlighted that combining oncolytic virus talimogene laherparepvec (TVEC) with neoadjuvant chemotherapy holds potential as a new triple-negative breast cancer treatment. The Phase II trial showed that TVEC, when added to systemic chemotherapy, may increase responses in high-risk, early-stage triple-negative breast cancer. Discover more of our news stories here >>>.
Looking to the future of immunotherapy in cancer treatment
Securing the top spot our most read article across all of 2023 focused on the evolving role of cancer immunotherapy. With the development of checkpoint inhibitors and immune-cell engagers and cell therapies, great strides have been made, however, there is still a need for more effective therapies for cancer patients who do not respond to these treatments or those who develop resistance. This articles explores this concept and look towards the future.
We hope you’ve enjoyed our round-up of the most read stories from across Oncology Central in 2023. Interested in more top content? View more in key topic areas now including immunotherapy, breast cancer, drug approval news and personalized medicine.
